ClinicalTrials.gg
CompletedNCT03332485Updated Mar 19, 2018

Safety and Efficacy Study of an Edible Colonoscopy Preparation

A Phase 2 interventional study of ECP Colon Prep Kit and MoviPrep® in Colon Prep for Colonoscopy, sponsored by Sebela Pharmaceuticals Development LLC. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-19.

Sponsored by Sebela Pharmaceuticals Development LLC (part of Sebela Pharmaceuticals) · Phase 2, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of ECP (PEG 3350) Colon Prep Kit compared with MoviPrep split-dose as a colon-cleansing preparation for colonoscopy.

02

Conditions studied

  • Colon Prep for Colonoscopy
03

In context

Lead sponsor

This is the only study on the registry with Sebela Pharmaceuticals Development LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled to undergo a medically indicated colonoscopy for colorectal cancer screening or surveillance for colorectal cancer
  • Females must be non-lactating and have a negative pregnancy test if of child bearing potential
  • Ability and willingness of subject to participate fully in all aspects of this clinical trial
  • Written

Exclusion criteria

Exclusion Criteria:

  • Known or suspected intestinal stricture of any etiology
  • History of diabetes mellitus, controlled with insulin
  • Taking insulin by injection
  • Pregnant or lactating
  • Renal insufficiency, hypokalemia, hyperkalemia, chronic liver disease or arrhythmic disorder
  • Chronic heart failure or recent (within 90 days of screening) acute heart failure
  • Receiving warfarin, heparin, clopidogrel, Pradaxa®, Xarelto®, Effient® or other blood thinning agents
  • Short bowel syndrome
  • Known diagnosis of Crohn's disease or ulcerative colitis, exclusionary only if subject has a history of any bowel resection, has suspected active inflammation, has symptoms suggestive of obstruction or a known bowel stricture
  • Severe psychological disease causing functional impairment limiting capacity to complete the preparation
  • Impaired consciousness increasing the risk of aspiration
  • Used narcotics/opiates within the 14 days prior to the colonoscopy
  • Used an anti-diarrheal within the 14 days prior to the colonoscopy procedure
  • Uses drugs of abuse including abused prescription medication
  • Used iron supplements within 14 days of the colonoscopy procedure
  • History of gastrointestinal surgery other than appendectomy or cholecystectomy
  • Diagnosis of gastroparesis or ileus
  • Symptoms of chronic constipation defined as fewer than 3 bowel movements per week on average over the previous 3 months
  • History of a failed bowel preparation, defined as either requiring an enema the day of the colonoscopy or needing to have the colonoscopy repeated
  • grade 1 sodium, potassium or magnesium at screening
  • Clinically significant abnormalities (ketones, protein, glucose) at screening urinalysis, in the opinion of the investigator
  • Any known allergies to any of the ingredients or ECP Colon Prep Kit (including coconut) or the active comparator
  • Unable or unwilling to consume all components of the study drug including aversions to or adverse events from flavoring
  • Received any therapy within 30 days of initiation of study drug
  • Serious underlying disease that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study
  • Requirement to use chromoendoscopy during the procedure for the purpose of surveillance for colorectal dysplasia or cancer in subjects with inflammatory bowel disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ECP Colon Prep Kit

    Drug: ECP Colon Prep Kit

  • Active comparator
    MoviPrep®

    Drug: MoviPrep®

Interventions

  • DrugECP Colon Prep Kit

    ECP Colon Prep Kit

  • MoviPrep®

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with successful bowel cleansing defined as centrally read 4 point modified Aronchick Scale (1=Inadequate, 2=Fair, 3=Good, 4=Excellent) score of either good or excellent.

    Time frame: 24-hour period, beginning the day prior to the procedure and through the morning of the colonoscopy procedure.

07

Study locations

8 sites
  • Sebela Site 007
    Anaheim, California 92801, United States
  • Sebela Site 006
    Indianapolis, Indiana 46202, United States
  • Sebela Site 002
    Bastrop, Louisiana 71220, United States
  • Sebela Site 003
    Annapolis, Maryland 21401, United States
  • Sebela Site 004
    Great Neck, New York 11023, United States
  • Sebela Site 008
    Wilmington, North Carolina 28403, United States
  • Sebela Site 001
    Mentor, Ohio 44060, United States
  • Sebela Site 005
    Ogden, Utah 84405, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2017
First posted
Nov 6, 2017
StartActual
Nov 20, 2017
Primary completionActual
Mar 14, 2018
CompletionActual
Mar 14, 2018
Last update
Mar 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03332485
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 20, 2017
Primary completion
Mar 14, 2018
Completion
Mar 14, 2018
Last update
Mar 19, 2018

Study contacts

Sue Hall
study director · Sebela Pharmaceuticals Development LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion